According to the latest report by IMARC Group, titled "Lung Marker Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026," the global [url=https://www.imarcgroup.com/lung-marker-market]lung marker market[/url] to grow at a CAGR of around 11% during the forecast period 2021-2026. Lung markers refer to substances produced by tumor cells for lung localization. There are mainly five types of lung markers, namely squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), cytokeratin 16 fragment (CYFRA), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (pro-GRP). These are generated in response to cancer and are locally found in the blood, urine, and stool of a patient. Lung markers are used during lung intervention procedures to detect, predict, diagnose, and monitor the tumor. They are also used with imaging tests and biopsy to establish an effective treatment plan. Get a sample copy of this Report: [url]https://www.imarcgroup.com/lung-marker-market/requestsample[/url]
Global Lung Marker Market Trends:
The increasing prevalence of lung cancer and respiratory disorders is majorly driving the global lung marker market growth. Additionally, continuous investments in research and development (R&D) activities and the implementation of favorable policies by governments of various nations for the early diagnosis and pre-treatment of chronic diseases are supporting the market growth. Apart from this, the increasing usage of lung markers in the healthcare sector for thoracoscopic surgeries is further creating a positive outlook for the market.
View Full Report with TOC & List of Figure: [url]https://www.imarcgroup.com/lung-marker-market[/url]
Competitive Landscape with Key players:
The report has also analysed the competitive landscape of the market with some of the key players being.
Abbott Diagnostics Ltd.
Affymetrix Inc.
Agilent Technologies Inc.
Beckman Coulter
Fujirebio US
Hologic Inc.
Roche
Siemens Healthineers
Thermo Fisher Scientific.
Veridex LLC
Lung Marker Market Segmentation:
Our report has categorized the market based on region, cancer type, marker type and end use industry.
Breakup by Cancer Type:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Breakup by Marker Type:
EGFR
EML4-ALK
KRAS
BRAF
Others
Breakup by End User:
Hospitals
Diagnostic Labs
Others
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
Contact US:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800